via Genetic Engineering and Biotechnology News
Understanding how drugs work is an important step in developing new treatments for COVID-19, says U of A virologist
A group of University of Alberta researchers who have discovered why the drug remdesivir is effective in treating the coronaviruses that cause Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) expect it might also be effective for treating patients infected with the new COVID-19 strain.
“Even if you know a drug works, it can be a red flag if you don’t know how it works,” said virologist Matthias Götte. “It is reassuring if you know exactly how it works against the target.
“We know the drug works against different coronaviruses, like MERS and SARS, and we know the novel coronavirus is very similar to SARS. So I would say I’m cautiously optimistic that the results our team found with remdesivir and MERS will be similar with COVID-19.”
The study, published in the Journal of Biological Chemistry this week, is among the first in Canada to discuss the COVID-19 strain.
Until now, there has not been a published explanation of why remdesivir may work against coronaviruses, said Götte, who added his study is an important step in answering that question.
Developed by Gilead Sciences as a response to the 2014 West African Ebola virus epidemic, remdesivir was first used on a patient with the novel coronavirus earlier this year in the United States.
As reported in the New England Journal of Medicine, the patient was given the drug on the seventh day of illness, and showed marked improvement the following day, with symptoms eventually disappearing altogether. And at a recent press conference in Beijing, the assistant director-general of the World Health Organization, Bruce Alyward, said remdesivir is the only drug available that may have real efficacy against COVID-19.
“What our study showed was that remdesivir essentially mimics one of the natural building blocks for RNA synthesis necessary for genome replication of the virus. Enzymes within the virus are synthesizing the viral RNA genome with these building blocks, but they mix up the bits they need with the drug. Once the drug is incorporated into the growing RNA chain, the virus can no longer replicate,” explained Götte.
He said the next step is to wait for results from ongoing clinical trials with remdesivir, which are expected by the end of April. Even then, that won’t be the end of the story, he cautioned.
“It’s likely we’ll need more than one drug to properly fight emerging diseases like COVID-19, as we have with HIV and hepatitis C virus infections,” Götte said.
“Ideally, we will have a couple of drugs because certain strains could be resistant to certain treatments.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19
- Stormont Executive Covid-19 meetings were chaotic and embarrassing, Naomi Long says
Meetings of the Stormont Executive in late 2020 to consider extending Covid lockdown measures in Northern Ireland were characterised by “chaotic and frankly embarrassing horse-trading”, Naomi Long has said.
- Mistrust, fights and blood sport: How COVID-19 trauma is shaping the 2024 election
Americans want to forget about COVID-19, but fallout from the pandemic is shaping voter attitudes about the nation's economy and divisive politics heading into a Biden-Trump rematch.
- Covid-19 inquiry in Belfast
Speaking at the inquiry today: Naomi Long MLA (Minister for Justice, Northern Ireland)Edwin Poots MLA (former Minister for Agriculture, Environment and Rural Affairs, Northern Ireland) Sir Brandon Lewis MP (former Secretary of State for Northern Ireland)
- Memorial pays tribute to COVID-19 victims
Green-Wood Cemetery is home to a new memorial for people who died of COVID-19 complications. The cemetery collaborated with Naming the Lost
- Minnesotans struggle to escape COVID-19's tentacles
For most of us COVID-19 is thankfully in our rearview mirrors. But for some the symptoms still linger, having never lost its grip. In Talking Points, Esme Murphy spoke with experts who working to track and treat long COVID.
Go deeper with Google Headlines on:
COVID-19
[google_news title=”” keyword=”COVID-19″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Coronaviruses
- COVID-19 effects linger on
It's been a year since Japan downgraded COVID-19 to the same level as seasonal flu, but for some, the coronavirus is still far from over.
- Mistrust, fights and blood sport: How COVID-19 trauma is shaping the 2024 election
Americans want to forget about COVID-19, but fallout from the pandemic is shaping voter attitudes about the nation's economy and divisive politics heading into a Biden-Trump rematch.
- San Diego biotech news: Local maker of mRNA used in COVID-19 vaccine opens new facility
The local manufacturing facility will support the growing momentum behind mRNA-based medicines and vaccines beyond COVID-19.
- AstraZeneca pulls its COVID-19 vaccine from the European market
The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator.
- CDC warns that new COVID-19 variants, nicknamed FLiRT, found in wastewater
The Centers for Disease Control and Prevention is warning the public of a new set of COVID-19 variants, nicknamed FLiRT, that were recently found in wastewater.
Go deeper with Google Headlines on:
Coronaviruses
[google_news title=”” keyword=”coronaviruses ” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]